SAN FRANCISCO -- Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled with the addition of an investigational targeted therapy to ...
CHICAGO — More is not better when it comes to inhibition of the androgen receptor in men with metastatic castration-resistant prostate cancer (mCRPC), the Alliance study shows. Indeed, treating ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback